PL EN


Preferences help
enabled [disable] Abstract
Number of results
2010 | 8 | 2 | 123-131
Article title

Chemioterapia w ciąży

Content
Title variants
EN
Chemotherapy during pregnancy
Languages of publication
EN PL
Abstracts
EN
Chemotherapy in the treatment of malignant tumors in pregnant women potentially threatens life and development of the fetus. Aim of paper: The purpose of this paper was to update current knowledge concerning the role of chemotherapy in combination therapy of gynecologic malignancies complicating pregnancy and to review available literature focusing on potential sequels of administration of chemotherapeutics at different time-points in pregnancy, with particular emphasis on fetal development, course of pregnancy and future lot of the child. Method: The PubMed database was searched using the following key words: methotrexate; 5-fluorouracil; aminopterin; thioguanine; mercaptopurine; cyclophosphamide; busulfan; ifosfamide; chlorambucil; dacarbazine; doxorubicin; daunorubicin; adriamycin; idarubicin; epirubicin; dactinomycin; bleomycin; mitoxantrone; vincristine; vinblastine; vinorelbine; paclitaxel; docetaxel; cisplatin; carboplatin; prednisone; tamoxifen; etoposide; teniposide; allopurinol; malformation; IUGR; chemotherapy; pregnancy. Search criteria were fulfilled by 33 papers (selected chemotherapeutic agent/pregnancy/malformation), which subsequently underwent content-related analysis. Conclusions: A decision on the use of chemotherapy during pregnancy should be made depending on type and stage of malignancy. It at all possible, administration of cytostatics should be delayed until the end of first trimester. If the patient requires multidrug therapy in the first trimester, she should receive anthracycline-derived antibiotics combined with Vinca alkaloids or should be placed on monotherapy and after 12 weeks shift to a multidrug regimen. Delivery should be planned for the 35th gestational week and 2-3 weeks after termination of chemotherapy in order to allow recovery of bone-marrow function.
PL
Chemioterapia w leczeniu nowotworów złośliwych u kobiet w ciąży stanowi potencjalne zagrożenie dla życia i rozwoju płodu. Celem pracy było przybliżenie wiedzy na temat udziału chemioterapii w leczeniu skojarzonym nowotworów ginekologicznych wikłających ciążę oraz dokonanie przeglądu doniesień medycznych pod kątem skutków zastosowania poszczególnych czynników chemioterapeutycznych w różnych trymestrach ciąży, ze szczególnym uwzględnieniem wpływu na rozwój płodu, przebieg ciąży i dalsze losy dziecka. Metoda: Przy użyciu słów kluczowych: methotrexate; 5-fluorouracil; aminopterin; thioguanine; mercaptopurine; cyclophosphamide; busulfan; ifosfamide; chlorambucil; dacarbazine; doxorubicin; daunorubicin; adriamycin; idarubicin; epirubicin; dactinomycin; bleomycin; mitoxantrone; vincristine; vinblastine; vinorelbine; paclitaxel; docetaxel; cisplatin; carboplatin; prednisone; tamoxifen; etoposide; teniposide; allopurinol; malformation; IUGR; chemotherapy; pregnancy przeszukano bazę PubMed. Odnaleziono 33 artykuły anglojęzyczne spełniające kryteria wyszukiwania (wybrany czynnik chemioterapeutyczny/ciąża/malformacja), które poddano analizie merytorycznej. Wnioski: Decyzję o chemioterapii w ciąży należy podjąć stosownie do rodzaju nowotworu i jego stopnia zaawansowania klinicznego. Jeśli jest to tylko możliwe, należy odroczyć podawanie cytostatyków do końca pierwszego trymestru. W sytuacji, w której pacjentka wymaga terapii wielolekowej w pierwszym trymestrze, należy rozważyć zastosowanie antybiotyków antracyklinowych w połączeniu z alkaloidami Vinca lub rozpocząć leczenie terapią jednolekową i po 12 tygodniach przejść na schemat wielolekowy. Poród powinien być zaplanowany na 2 do 3 tygodni po zakończeniu chemioterapii, w celu umożliwienia powrotu prawidłowej czynności szpiku (około 35. tygodnia).
Discipline
Year
Volume
8
Issue
2
Pages
123-131
Physical description
References
  • 1. Pavlidis N.A.: Coexistence of pregnancy and malignancy. Oncologist 2002; 7: 279-287.
  • 2. Pereg D., Koren G., Lishner M.: Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat. Rev. 2008; 34: 302-312.
  • 3. Donegan WL.: Cancer and pregnancy. CA Cancer J. Clin. 1983; 33: 194-214.
  • 4. Koren G., Lishner M., Santiago S. (red.): The Motherisk guide to cancer in pregnancy and lactation. Wyd. 2, Moth-erisk Program, Toronto 2005.
  • 5. Doll D.C., Ringenberg Q.S., Yarbro J.W: Antineoplastic agents and pregnancy. Semin. Oncol. 1989; 16: 337-345.
  • 6. Zemlickis D., Lishner M., Degendorfer P. i wsp.: Fetal outcome after in utero exposure to cancer chemotherapy. Arch. Intern. Med. 1992; 152: 573-576.
  • 7. Williams S.F., Schilsky R.L.: Antineoplastic drugs administered during pregnancy. Semin. Oncol. 2000; 27: 618-622.
  • 8. Williams S.F., Bitran J.D.: Cancer and pregnancy. Clin. Per-inatol. 1985; 12: 609-623.
  • 9. Amant F., Brepoels L., Halaska M.J. i wsp.: Gynaecologic cancer complicating pregnancy: an overview. Best Pract. Res. Clin. Obstet. Gynaecol. 2010; 24: 61-79.
  • 10. Zhang J., Liu G., Wu J. i wsp.: Pregnancy-associated breast cancer: a case control and long-term follow-up study in China. J. Exp. Clin. Cancer Res. 2003; 22: 23-27.
  • 11. Nugent P., O’Connell T.X.: Breast cancer and pregnancy. Arch. Surg. 1985; 120: 1221-1224.
  • 12. Kahlert S., Bauerfeind I., Strauss A., Untch M.: Breast cancer treatment during pregnancy-experiences in the department of OB/GYN Grosshadern-Munich and review of international data. Zentralbl. Gynakol. 2004; 126: 159-166.
  • 13. Janni W, Hepp P., Nestle-Kraemling C. i wsp.: Treatment of pregnancy-associated breast cancer. Expert Opin. Pharma-cother. 2009; 10: 2259-2267.
  • 14. Hunter M.I., Monk B.J., Tewrai K.S.: Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. Am. J. Obstet. Gynecol. 2008; 199: 3-9.
  • 15. Pettersson B.F., Andersson S., Hellman K, Hellstrom A.C.: Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience. Cancer 2010; 116: 2343-2349.
  • 16. Caluwaerts S., VAN Calsteren K., Mertens L. i wsp.: Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature. Int. J. Gynecol. Cancer 2006; 16: 905-908.
  • 17. Riggs C.E.: Clinical pharmacology of individual antineoplastic agents. W: Moossa A.R., Robson M.C., Schimpff S.C. (red.): Comprehensive Textbook of Oncology. Lippincott, Williams and Wilkins, Baltimore 1986: 210-234.
  • 18. Warkany J., Beaudry P.H., Hornstein S.: Attempted abortion with aminopterin (4-amino-pteroylglutamic acid); malformations of the child. AMA J. Dis. Child 1959; 97: 274-281.
  • 19. Feldkamp M., Carey J.C.: Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993; 47: 533-539.
  • 20. Giacalone PL., Laffargue F., Bénos P.: Chemotherapy for breast carcinoma during pregnancy: a French national survey. Cancer 1999; 86: 2266-2272.
  • 21. Reynoso E.E., Huerta F.: Acute leukemia and pregnancy - fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol. 1994; 33: 703-716.
  • 22. Volkenandt M., Buchner T., Hiddemann W, van de Loo J.: Acute leukaemia during pregnancy. Lancet 1988; 1: 1404.
  • 23. Plows C.W: Acute myelomonocytic leukemia in pregnancy: report of a case. Am. J. Obstet. Gynecol. 1982; 143: 41-43.
  • 24. Greenlund L.J., Letendre L., Tefferi A.: Acute leukemia during pregnancy: a single institutional experience with 17 cases. Leuk. Lymphoma 2001; 41: 571-577.
  • 25. O’Donnell R., Costigan C., O’Connell L.G.: Two cases of acute leukaemia in pregnancy. Acta Haematol. 1979; 61: 298-300.
  • 26. Cardonic E., Iacobucci A.: Use of chemotherapy during human pregnancy. Lancet Oncol. 2004; 5: 283-291.
  • 27. Cantini E., Yanes B.: Acute myelogenous leukemia in pregnancy. South. Med. J. 1984; 77: 1050-1052.
  • 28. Turchi J.J., Villasis C.: Anthracyclines in the treatment of malignancy in pregnancy. Cancer 1988; 61: 435-440.
  • 29. Ebert U., Loffler H., Kirch W: Cytotoxic therapy and pregnancy. Pharmacol. Ther. 1997; 74: 207-220.
  • 30. Karp G.I., von Oeyen P., Valone F. i wsp.: Doxorubicin in pregnancy: possible transplacental passage. Cancer Treat. Rep. 1983; 67: 773-777.
  • 31. Murray C.L., Reichert J.A., Anderson J., Twiggs L.B.: Multimodal cancer therapy for breast cancer in the first trimester of pregnancy: a case report. JAMA 1984; 252: 2607-2608.
  • 32. Scialli A.R., DeSesso J.M., Goeringer G.C.: Taxol and embryonic development in the chick. Teratog. Carcinog. Mutagen. 1994; 14: 23-30.
  • 33. Requena A., Velasco J.G., Pinilla J., Gonzalez-Gonzalez A.: Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases. Eur. J. Obstet. Gynecol. Reprod. Biol. 1995; 63: 139-141.
  • 34. Rosner F.: Acute leukemia as a delayed consequence of cancer chemotherapy. Cancer 1976; 37 (supl. 2): 1033-1036.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-7dc3eed8-6b6c-4009-8289-3b5f6f565c3b
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.